P- 28 ATORVASTATIN SHOWS ANTI-PROMOTOR AND ANTI-NEOANGIOGENIC EFFECT IN HEPATOCELLULAR CARCINOMA DEVELOPMENT IN VIVO AND IN VITRO MODEL BY INHIBITING TGF-β1/pERK SIGNALING PATHWAY
Introduction and Objectives: Hepatocellular carcinoma (HCC) represents 90% of liver tumors. Statins may reduce HCC incidence. Its antitumor activities are controversial and may be mediated by disrupting several hepatocarcinogenic pathways. This study aimed to evaluate in vivo and in vitro the anti-p...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2023-03-01
|
| Col·lecció: | Annals of Hepatology |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1665268123000340 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|